We demonstrated that ER+/PR− breast cancers are biologically characterized by relevant molecular characteristics in terms of prognostic and predictive information, which could be integrated into the clinical setting to realize the potentials of precision medicine in these clinically, and pathologically, challenging neoplasms. This evidence concerns the gene ESR1 and neoplasm.